Costs of Robotic-Assisted Radical Prostatectomy 1 Year After Surgery: Pay Now and Save Later?
Menée dans un contexte américain à partir de données portant sur 11 457 patients atteints d'un cancer de la prostate (âge : 18-64 ans), cette étude de cohorte rétrospective compare, 1 an après les traitements anticancéreux, les coûts de santé liés à l'utilisation d'une prostatectomie radicale par voie ouverte et à une utilisation d'une prostatectomie radicale assistée par robot
As the US population changes due to aging and growth, the annual costs for cancer-related medical care in 2030 are projected to reach more than $220 billion.1 The combination of a growing and aging population with the rising percentage of the US gross domestic product spent on health care services underscores the importance of measuring the cost and value of care. Measuring the cost of care is complex. This is because costs can be a function of perspective: cost to the hospital, to the payer, to the patient, and ultimately to society. Attempts to measure cost are often performed from one of these perspectives and measure health care services in a defined setting (eg, a single admission) and during a short period of time. However, measuring the true cost of care requires considering health care services that span multiple locations and longer time periods.2 Elsewhere in JAMA Network Open, Okhawere et al3 present a retrospective review of MarketScan claims data to compare the total health care costs, health care utilization, and extrapolated days off work within 1 year following open vs robotic-assisted radical prostatectomy.3
JAMA Network Open , commentaire en libre accès, 2020